Surrozen Inc (SRZN)
Healthcare
Biotechnology
21.80 $
-1.9%
vs. previous close
Closing price · As of: 3. Aug 2026
Surrozen Inc (SRZN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -30 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -21 | -29 | -49 | -44 | -40 | -18 | -30 | |
| 2.3 | 1.9 | 2.1 | 2.0 | 1.9 | 1.4 | 0.5 | |
| 0.8 | 0.6 | 2.3 | 4.5 | 4.4 | 4.1 | 3.8 | |
| 1.5 | 1.6 | 4.0 | – | – | – | – | |
| -1.1 | 0.1 | -0.2 | -8.4 | -3.9 | -0.8 | 3.2 | |
| 1.6 | 0.9 | 1.3 | 0.7 | 0.4 | 0.0 | 0.1 | |
| -1.6 | -15 | -78 | 38 | 52 | 0.0 | -0.1 | |
| – | 48 | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | -2.6 | 0.0 | 0.1 | 0.2 | |
| 29 | 50 | 125 | -2.6 | 0.3 | 16 | 85 | |
| 30 | 5.9 | -1.9 | -8.4 | 12 | -1.5 | 55 | |
| -23 | -30 | -50 | -45 | -41 | -18 | -30 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.